Amylyx Pharmaceuticals, Inc.
AMLX
$9.28
$0.8510.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.99% | 69.77% | -893.62% | -447.98% | -429.35% |
| Total Depreciation and Amortization | -32.21% | -50.48% | -46.84% | -26.82% | -25.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.30% | -95.65% | -27.02% | 439.51% | 83.34% |
| Change in Net Operating Assets | 214.58% | -5,711.59% | -1,815.03% | 68.89% | 59.95% |
| Cash from Operations | 62.08% | -8,043.97% | -535.45% | -704.22% | -873.38% |
| Capital Expenditure | 80.90% | 83.58% | 94.38% | -10,035.57% | 67.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 179.70% | -5,026.41% | 205.44% | 169.62% | -123.38% |
| Cash from Investing | 179.40% | -5,430.77% | 210.54% | 135.91% | -123.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 53.19% | -32.92% | -57.35% | -50.10% | -97.79% |
| Repurchase of Common Stock | -415.00% | 32.70% | 67.52% | -332.63% | 97.30% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -214.81% | 50,023.66% | -52.17% | -91.00% | -98.05% |
| Foreign Exchange rate Adjustments | 1,658.97% | 279.09% | -321.52% | 276.12% | -116.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.24% | -5,121.08% | -84.10% | 97.83% | -171.74% |